PROM1 and neoplasm: Of 13 tumour samples, 9 comprised of CD133+ sub-populations representing >20% of epithelial cells co-staining for EpCAM, with one late-stage tumour (case 12) exhibiting CD133 expression on 85% of the EpCAM+ population (Table 1).